SCHEMBL15765015

SCHEMBL15765015

CC(=O)c1scc(C)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.39
GSK3B P49841 2/20 0.38
GPR35 Q9HC97 1/20 0.34
MAPT P10636 2/20 0.33
PKM P14618 1/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TP53 P04637 1/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
BRD4 O60885 1/20 0.33
CSNK1A1 P48729 1/20 0.32
CSNK1D P48730 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3836429 0.81 POLB (0.55) POLBTDP1L3MBTL1GAAGSK3B
SCHEMBL12261076 0.79 GPR35 (0.46) POLBTDP1L3MBTL1GSK3BGPR35
SCHEMBL9590823 0.79 POLB (0.40) POLBTDP1L3MBTL1GAAGSK3B
SCHEMBL7810682 0.79 GSK3B (0.41) POLBTDP1L3MBTL1GAAGSK3B
SCHEMBL17678405 0.77 KDM4E (0.37) POLBTDP1L3MBTL1GAAGSK3B
SCHEMBL4504634 0.77 POLB (0.43) POLBTDP1L3MBTL1GAAGSK3B
SCHEMBL25176315 0.77 GSK3B (0.39) POLBTDP1L3MBTL1GAAGSK3B
SCHEMBL14125042 0.77 KDM4E (0.41) POLBTDP1L3MBTL1GAAGSK3B
SCHEMBL11808790 0.76 POLB (0.38) POLBTDP1L3MBTL1GAAGSK3B
SCHEMBL167302 0.76 MAPT (0.51) POLBTDP1GAAMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 US disclosed
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 US disclosed
WO-2014085607-A1 SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2014-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof BCL6, MALT1, BCL3 POLB 3532/4885TDP1 3201/4885L3MBTL1 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.